Vanguard Group Inc Exelixis, Inc. Transaction History

Vanguard Group Inc

  • $6.44 Trillion
  • Q3 2025

A detailed history of Vanguard Group Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 26,064,571 shares of EXEL stock, worth $1.09 Billion. This represents 0.02% of its overall portfolio holdings.

Number of Shares
26,064,571
Previous 27,469,094 5.11%
Holding current value
$1.09 Billion
Previous $1.21 Billion 11.1%
% of portfolio
0.02%
Previous 0.02%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025
SELL
$36.22 - $46.25 $50.9 Million - $65 Million
-1,404,523 Reduced 5.11%
26,064,571 $1.08 Billion
Q2 2025

Aug 11, 2025
SELL
$34.13 - $46.26 $41.1 Million - $55.6 Million
-1,202,893 Reduced 4.2%
27,469,094 $1.21 Billion
Q1 2025

May 09, 2025
SELL
$32.38 - $39.16 $24.5 Million - $29.7 Million
-757,265 Reduced 2.57%
28,671,987 $1.06 Billion
Q4 2024

Feb 11, 2025
BUY
$25.39 - $36.46 $3.09 Million - $4.44 Million
121,750 Added 0.42%
29,429,252 $980 Million
Q3 2024

Nov 13, 2024
SELL
$21.96 - $27.6 $7.61 Million - $9.57 Million
-346,635 Reduced 1.17%
29,307,502 $761 Million
Q2 2024

Aug 13, 2024
SELL
$20.34 - $23.73 $23.7 Million - $27.7 Million
-1,165,646 Reduced 3.78%
29,654,137 $666 Million
Q1 2024

May 10, 2024
SELL
$20.17 - $23.93 $17.2 Million - $20.4 Million
-851,307 Reduced 2.69%
30,819,783 $731 Million
Q4 2023

Feb 14, 2024
SELL
$19.25 - $24.13 $7.7 Million - $9.66 Million
-400,130 Reduced 1.25%
31,671,090 $760 Million
Q3 2023

Nov 14, 2023
SELL
$19.04 - $22.74 $14.4 Million - $17.2 Million
-757,695 Reduced 2.31%
32,071,220 $701 Million
Q2 2023

Aug 14, 2023
SELL
$18.17 - $20.48 $5.28 Million - $5.95 Million
-290,315 Reduced 0.88%
32,828,915 $627 Million
Q1 2023

May 15, 2023
BUY
$16.3 - $19.41 $13.5 Million - $16.1 Million
830,216 Added 2.57%
33,119,230 $643 Million
Q4 2022

Feb 10, 2023
BUY
$14.96 - $17.39 $15 Million - $17.5 Million
1,004,182 Added 3.21%
32,289,014 $518 Million
Q3 2022

Nov 14, 2022
BUY
$15.68 - $22.27 $3.45 Million - $4.9 Million
220,099 Added 0.71%
31,284,832 $491 Million
Q2 2022

Aug 12, 2022
BUY
$17.44 - $23.16 $13.9 Million - $18.4 Million
795,961 Added 2.63%
31,064,733 $647 Million
Q1 2022

May 13, 2022
BUY
$17.03 - $22.67 $3.56 Million - $4.74 Million
209,083 Added 0.7%
30,268,772 $686 Million
Q4 2021

Feb 14, 2022
SELL
$15.84 - $21.88 $718,898 - $993,023
-45,385 Reduced 0.15%
30,059,689 $549 Million
Q3 2021

Nov 12, 2021
BUY
$16.3 - $21.14 $2.61 Million - $3.39 Million
160,194 Added 0.53%
30,105,074 $636 Million
Q2 2021

Aug 13, 2021
BUY
$17.95 - $25.56 $538 Million - $765 Million
29,944,880 New
29,944,880 $546 Million

Others Institutions Holding EXEL

# of Institutions
694
Shares Held
257M
Call Options Held
1.5M
Put Options Held
1.71M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email